Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of azacitidine (NS-17) in elderly patients with acute myeloid leukemia
jRCT2080223699Phase 2Completed
- Sponsor
- Nippon Shinyaku
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of azacitidine in acute myeloid leukemia (AML) (3 arms), sponsored by Nippon Shinyaku. Started Nov 2017; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080223699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223699.